2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What External and Internal Drivers Are Contributing to the Growth of theCongestive Heart Failure (CHF) Market?
The surging number of patients suffering from cardiovascular diseases is predicted to facilitate the expansion of the congestive heart failure (CHF) market. When referring to cardiovascular, it indicates the heart and blood vessels’ functions in circulating blood and keeping the overall health of the body intact. Rising cases of cardiovascular diseases can be attributed to inactive lifestyles, unhealthy eating habits, ageing population, and urbanization, which necessitates advanced healthcare and treatments. Congestive heart failure (CHF) proves beneficial for individuals with cardiovascular ailments as it offers customised solutions working on enhancing heart efficiency, alleviating symptoms, and averting complications, thus improving the overall patient care and health. For instance, the American College of Cardiology, a US-based nonprofit medical society, reported that cardiovascular disease cases escalated to 19.8 million in 2022. On top of that, Eastern Europe witnesses the highest mortality rate with 553 deaths per 100,000. Thus, the surge in cardiovascular patients contributes to the growth of the congestive heart failure (CHF) market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20730&type=smp
#What Long-Term Growth Rate is Expected for theCongestive Heart Failure (CHF) Market Between 2025 and 2034?
The market size for congestive heart failure (CHF) has experienced significant growth in the past few years. It’s expected to expand from $15.94 billion in 2024 to $17.10 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.2%. This development over the historical period can be credited to a high occurrence of an aging population, an increase in cardiovascular diseases, greater awareness about heart health, a rise in healthcare spending, and growing demand for remote patient monitoring.
The market size for congestive heart failure (CHF) is forecasted to witness robust growth in the approaching years. By 2029, it’s expected to surge to $22.31 billion, expanding at a compound annual growth rate (CAGR) of 6.9%. This growth during the prediction period can be credited to factors such as increased utilization of digital health solutions, the escalating prevalence of hypertension, growing rates of obesity, enhanced patient results, and a heightened emphasis on personalized medicine. Noteworthy trends during the forecast timeframe involve progress in diagnostic technologies, improvements in treatment methodologies, technological evolutions in imaging, innovative therapeutic strategies, and advancements in wearable health gadgets.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20730
Which Upcoming Market Trends and Innovations Are Set to Influence theCongestive Heart Failure (CHF) Market’s Path Forward?
Leading companies in the congestive heart failure (CHF) market are concentrating their efforts on cutting-edge innovations like single intracoronary infusion therapies. These are focused on providing effective treatment solutions that better heart function and improve the life quality of CHF patients. Single intracoronary infusions are delivered straight to the coronary artery, providing precise treatment to the heart, which is particularly beneficial for conditions such as CHF. For example, in January 2024, Bayer AG, a pharmaceutical company based in Germany, partnered with Asklepios Biopharmaceutical, Inc., an American biotech firm, to commence the GenePHIT Phase II trial for AB-1002, a potential gene therapy for CHF. The therapy intends to use genetic solutions to target non-ischemic cardiomyopathy, which could be a significant breakthrough for CHF treatment. The trial is adaptive, double-blind, placebo-controlled and aims to enroll 90 to 150 participants who have maintained medical stability for a minimum of four weeks and have a left ventricular ejection fraction from 15% to 35%.
Who Are the Dominant Market Players Pushing the Boundaries of theCongestive Heart Failure (CHF) Market?
Major companies operating in the congestive heart failure (CHF) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG., Medtronic Plc, Eli Lilly and Company, Canon Medical Systems Corporation, Novo Nordisk A/S, Jarvik Heart Inc., Boston Scientific Corporation, Applied Molecular Genetics Inc., Biotronik SE & Co. KG, Exelixis Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., LivaNova
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-chf-global-market-report
What Are the Core Segments of the Congestive Heart Failure (CHF) Market, and How Do They Contribute to Growth?
The congestive heart failure (CHF) market covered in this report is segmented –
1) By Type: Systolic Heart Failure, Diastolic Failure, Left-Sided Heart Failure, Right-Sided Heart Failure
2) By Treatment: Medication, Surgery
3) By Diagnosis: Electrocardiogram, Echocardiogram, Magnetic Resonance Imaging (MRI), Stress Test, Blood Tests, Cardiac Catheterization, Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings
Subsegments:
1) By Systolic Heart Failure: Reduced Ejection Fraction (HFrEF), Mild-to-moderate Reduced Ejection Fraction
2) By Diastolic Heart Failure: Preserved Ejection Fraction (HFpEF), Borderline Ejection Fraction (HFpEF)
3) By Left-Sided Heart Failure: Acute Left-Sided Heart Failure, Chronic Left-Sided Heart Failure
4) By Right-Sided Heart Failure: Acute Right-Sided Heart Failure, Chronic Right-Sided Heart Failure
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=20730&type=smp
What Regions Are Dominating the Congestive Heart Failure (CHF) Market Growth?
North America was the largest region in the congestive heart failure (CHF) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure (CHF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Congestive Heart Failure (CHF) Market 2025, By The Business Research Company:
Heating, Ventilation, And Air Conditioning Equipment Global Market Report 2025
Heart Attack Diagnostic Global Market Report 2025
https://thebusinessresearchcompany.com/report/heart-attack-diagnostic-global-market-report
Implantable Heart Pacemaker Global Global Market Report 2025
https://thebusinessresearchcompany.com/report/implantable-heart-pacemaker-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: